This study determines whether quercetin supplementation reduces the inflammation and oxidative stress markers in patients with chronic obstructive pulmonary disease. It is small study with 8 subjects receiving quercetin 1000 mg/day, 8 patients receiving 500 mg/day and 4 subjects receive placebo.
Phase:
PHASE2
Details
Lead Sponsor:
Temple University
Collaborators:
National Center for Complementary and Integrative Health (NCCIH) Quercegen Pharmaceuticals